Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19972301 | 0.86 | ALDH1A1 (0.36) | HTTALDH1A1MAPTKMT2A | |
| SCHEMBL19972227 | 0.84 | KMT2A (0.38) | ALDH1A1MAPTTP53HSD17B10KMT2A | |
| SCHEMBL1096505 | 0.83 | KCNA5 (0.37) | ALDH1A1KCNA5KMT2A | |
| SCHEMBL19988401 | 0.81 | KDM4E (0.37) | GAAALDH1A1MAPTTP53HSD17B10 | |
| SCHEMBL4428619 | 0.77 | ALDH1A1 (0.48) | HTTGAAALDH1A1MAPTKCNA5 | |
| SCHEMBL1105718 | 0.76 | KCNA5 (0.40) | HTTALDH1A1MAPTKCNA5KMT2A | |
| SCHEMBL14920601 | 0.75 | HTT (0.34) | HTTALDH1A1MAPTKCNA5KMT2A | |
| SCHEMBL19985861 | 0.74 | KMT2A (0.38) | ALDH1A1MAPTTP53HSD17B10KMT2A | |
| SCHEMBL28621086 | 0.74 | KMT2A (0.36) | GAAALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL1096969 | 0.74 | KCNA5 (0.51) | GAAALDH1A1KCNA5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962601-B1 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-1921917-B1 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1819674-B1 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-8017624-B2 | Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7943615-B2 | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7884104-B2 | Such as (3R,4R)-1-Pyrimidin-4-yl-4-(2,4,5-trifluorophenyl)piperidin-3-amine bis-trifluoroacetic acid salt | MERCK SHARP & DOHME CORP. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1796669-B1 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7718667-B2 | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2009-10-15 | — | — | US | disclosed |
| US-20090233936-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-4 Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1962601-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1921917-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-10 | — | — | US | disclosed |
| EP-1819674-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007070434-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1796669-A2 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007024993-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006058064-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006039325-A2 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | HTT 2609/4885GAA 215/4885ALDH1A1 1432/4885 |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | HTT 3045/4885GAA 240/4885ALDH1A1 1070/4885 |
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | HTT 2638/4885GAA 171/4885ALDH1A1 1471/4885 |
| US-20090233936-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-4 Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP7, DPP3 | HTT 3741/4885GAA 120/4885ALDH1A1 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.